Positive Ph III VELOUR results with Sanofi's Zaltrap

French drug major Sanofi (Euronext: SAN) says that positive detailed results from the pivotal Phase III VELOUR study evaluating Zaltrap (aflibercept) Injection for Intravenous Infusion for the treatment of patients with previously treated metastatic colorectal cancer have been published in the October edition of the Journal of Clinical Oncology (JCO).

In the VELOUR trial evaluating metastatic colorectal cancer patients previously treated with an oxaliplatin-containing regimen, Zaltrap in combination with the FOLFIRI chemotherapy regimen (5-fluorouracil, leucovorin, irinotecan) showed a statistically-significant improvement in overall survival, progression-free survival, and the overall tumor response rate versus placebo plus FOLFIRI.

Debasish Roychowdhury, senior vice president and head of Sanofi Oncology, commented: “The scrutiny of the FDA review and peer review processes should provide physicians confidence in the results of VELOUR, as they make important decisions for their patients.”